pha-665752 hydrate 98% (hplc) - small molecule inhibitor for cancer research

REF #: 3199813
Procurenet
Short description

pha-665752 hydrate 98% (hplc) – small molecule inhibitor for cancer research

  • purity: ≥98% (hplc)
  • chemical name: ((3z)-5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-[[(2r)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-1h-pyrrol-2-yl]methylene]-1,3-dihydro-2h-indol-2-one)
  • part of äs library of pharmacologically activpz0147
  • chemical formula: c28h31cl2n5o4s
  • molecular weight: 611.55 g/mol

this product is a hydrate form of pha-665752, a potent and selective small molecule inhibitor of tumor growth and angiogenesis. it has shown activity against multiple cancer types in preclinical studies.

$0
Quantity :
  • Procurenet Team Tshim Sha Tsui
    Hong Kong Hong Kong 3 years
Delivery options
  • 7 Days Return Back Policy
  • 2 Days Cancellation Policy
  • Ship Only
Description

pha-665752 hydrate 98% (hplc) - small molecule inhibitor for cancer research is a highly pure and potent compound designed for use in cancer research. with a purity of 98% as determined by high-performance liquid chromatography (hplc), this small molecule inhibitor is ideal for studying tumor growth inhibition and angiogenesis suppression.

product features:

  • potent inhibitor of tumor growth: pha-665752 hydrate has shown significant activity against various cancer types, making it a valuable tool for investigating tumor biology.
  • selective angiogenesis inhibition: by specifically targeting the signaling pathways involved in angiogenesis, this compound effectively suppresses the formation of new blood vessels and limits tumor growth.
  • high purity and quality control: pha-665752 hydrate is synthesized and purified using advanced techniques, ensuring a purity of 98% as determined by hplc. this guarantees minimal impurities that may affect experimental results.
  • part of lopac library: as a member of the library of pharmacologically active compounds (lopac), pha-665752 hydrate undergoes rigorous quality control measures and extensive characterization. its inclusion in this prestigious collection confirms its value as a well-studied and reliable research tool.
  • hydrate form for improved stability: provided as a hydrate form, this compound offers enhanced stability during storage and handling, ensuring consistent performance and reliable results in experiments.

product description:

pha-665752 hydrate 98% (hplc) is a high-purity small molecule compound designed for use in cancer research. it is part of library of pharmacologically active compounds (lopac), which is a collection of well-characterized bioactive compounds used for drug discovery and screening applications.

the chemical name of pha-665752 hydrate is ((3z)-5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-[[(2r)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]carbonyl]-1h-pyrrol-2-yl]methylene]-1,3-dihydro-2h-indol-2-one). it has a chemical formula of c28h31cl2n5o4s and a molecular weight of 611.55 g/mol.

pha-665752 hydrate has been extensively studied for its potential as an anticancer agent. its unique molecular structure and mechanism of action make it a promising candidate for inhibiting tumor growth and angiogenesis. it can be used in various in vitro and in vivo assays to study the effects of tumor growth inhibition and angiogenesis suppression. additionally, it is valuable in investigating the molecular mechanisms involved in angiogenesis and developing novel therapeutic strategies targeting this process. given its promising activity against multiple cancer types, pha-665752 hydrate holds potential for further development as a therapeutic agent.

overall, pha-665752 hydrate is a highly pure and potent small molecule inhibitor with demonstrated activity against tumor growth and angiogenesis. its inclusion in lopac library attests to its quality and reliability as a research tool. researchers in the field of cancer biology and drug discovery can utilize this compound to gain insights into tumor biology and explore its potential as a therapeutic agent.

All categories
Filters